Blog Posts

Baldwin, a 340B Entity Ally, Will Chair Senate Health Appropriations Subcommittee

Tammy Baldwin
U.S. Sen. Tammy Baldwin (D-Wis.) is the new chair of the Senate Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee.

U.S. Sen. Tammy Baldwin (D-Wis.), who has a long track record of support for 340B covered entities, is the new leader of a Senate Appropriations subcommittee with influence over 340B policy.

Baldwin announced yesterday she will serve

Read More »

340B Pricing May Be Coming to Contrast Agents, Radiopharmaceuticals, and OTC Monograph Drugs

Contrast media
Providers may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and OTC monograph drugs thanks to language in a a federal FY 2023 spending law.

Health care providers in the coming months may get previously unavailable access to 340B pricing on contrast agents, radiopharmaceuticals, and so-called “OTC monograph” drugs thanks to language tucked into the massive fiscal year 2023 federal spending bill signed

Read More »

Ex-CMS Leader Verma: Big Health Systems Use 340B to Expand Profit and Monopoly Power

Seema Verma
Health systems use 340B to expand "their profit and monopoly power," Trump administration CMS Administrator Seema Verma said in a Wall Street Journal op-ed.

Seema Verma, ex-President Trump’s Centers for Medicare & Medicaid Services administrator, said in a Wall Street Journal op-ed yesterday that large health systems work to expand their use of the 340B program “and thus their profit and monopoly

Read More »

340B Policies and Procedures: The Keys to Compliant Savings

SPONSORED CONTENT

For 340B covered entities (CEs), a Health Resources and Services Administration (HRSA) audit is an inevitability. While you won’t be able to predict when HRSA comes calling, you can bank on sooner or later being one of the 200 CEs HRSA audits every year. That’s why Cloudmed recommends keeping your

Read More »

CMS Seeks Input on Excluding 340B Drugs from New Medicare Part D Inflation Rebates

Part D inflation rebate
CMS is seeking comment on how best to exclude 340B drugs from new Part D inflation rebate invoices.

The U.S. Centers for Medicare & Medicaid Services is seeking comments by March 11 on “the most reliable way to identify” 340B-purchased drugs dispensed to Medicare Part D beneficiaries so they can be excluded from new Part D

Read More »

Kansas Bill Targets 340B Contract Pharmacy Limits, Rhode Island Bill Targets PBM Policies

Kansas Capitol
A bill in Kansas would prohibit drug manufacturers from denying 340B covered entities access to a manufacturers’ products if the entities use contract pharmacies.

Kansas lawmakers have introduced a bill to prohibit drug manufacturers from denying 340B covered entities access to a manufacturers’ products if the entities use contract pharmacies.

The legislation, like bills recently rolled out in other states, is modeled

Read More »

Sanders, Asked About Abuse in 340B, Cites His Past Effort to End a Hospital’s Tax Exemption

Sanders
Senate HELP chair Bernie Sanders (I-Vt.) talked about taking away hospitals' tax-exempt status when he was asked during an interview about alleged hospital abuse of 340B.

U.S. Sen. Bernie Sanders (I-Vt.), the new chair of the Senate committee that oversees the 340B program, recently answered a reporter’s question about alleged hospital abuse of 340B by noting that he tried to revoke a Burlington, Vt.,

Read More »

More Entities Might Share 340B Contract Pharmacy Claims Data if the Process Improves and Actually Restores 340B Pricing, Survey Shows

Data upload
More 340B entities would share contract pharmacy claims data with manufacturers if the process was better and got 340B pricing turned back on reliably, a survey by McKesson found.

While most 340B covered entities do not share their contract pharmacy claims data with drug makers to restore access to 340B pricing, many would do so if the process was better and got 340B pricing turned back on

Read More »

What’s the Secret to 340B and Specialty Pharmacy Provider and Patient Engagement?

SPONSORED CONTENT

The rise in digital technologies in the healthcare sector during the COVID-19 pandemic has resulted in some interesting trends in medical communication as we move closer to a post-pandemic world.

During the pandemic, patients became more engaged with medical communication than ever. They went from attending doctor’s visits in-person to making telehealth appointments. In addition, due to forced shutdowns, even the

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer